[{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase III","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"||MyD88\/CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-603","moa":"MyD88\/CD40","graph1":"Oncology","graph2":"IND Enabling","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rimiducid","moa":"Peptidyl-prolyl cis-trans isomerase FKBP1A; Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rimiducid","moa":"Peptidyl-prolyl cis-trans isomerase FKBP1A; Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"MTS Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Private Placement","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ MTS Securities","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ MTS Securities"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BPX-601","moa":"||Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"BPX-601","moa":"Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"BPX-601","moa":"Prostate stem cell antigen (PSCA)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon)","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BPX-701","moa":"T-cell receptor (TCR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BPX-501","moa":"T-cells (T-cells)","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"BPX-201 Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"iC9-CAR19 Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Rivogenlecleucel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Rivogenlecleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Rivogenlecleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bellicum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Rimiducid","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Bellicum Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Bellicum Pharmaceuticals","sponsor":"Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CD70.CAR NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bellicum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Bellicum Pharmaceuticals \/ Bellicum Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Bellicum Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : CD70.CAR NK Cell is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 10, 2025

                          Lead Product(s) : CD70.CAR NK Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : MD Anderson Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Fludarabine Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 10, 2024

                          Lead Product(s) : Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : MD Anderson Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Rimiducid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 04, 2023

                          Lead Product(s) : Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : MD Anderson Cancer Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : BPX-601 incorporates high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA). It is being discontinued following the company’s assessment of BPX-601 risk/benefit profile in combinati...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 14, 2023

                          Lead Product(s) : BPX-601,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : BPX-601 is our first clinical candidate incorporating our high-performance GoCAR-T™ technology designed to target and treat solid tumors expressing prostate stem cell antigen (PSCA).

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : BPX-601,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Proceeds from the financing will be used to support ongoing clinical development of BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          December 06, 2021

                          Lead Product(s) : BPX-601,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : MTS Securities

                          Deal Size : $35.0 million

                          Deal Type : Private Placement

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs. The CaspaCIDe switch consists of the CID-binding domain coupled to the signaling domain of caspase-9, an enzyme that is part of the ap...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : $5.0 million

                          September 01, 2021

                          Lead Product(s) : Undisclosed,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : BPX-603 is Bellicum’s first dual switch GoCAR-T product candidate that incorporates the company’s iMC activation and CaspaCIDe safety switch technologies. Phase 1/2 trial will investigate the safety, tolerability, and clinical activity of BPX-603, ad...

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 10, 2020

                          Lead Product(s) : BPX-603,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 07, 2020

                          Lead Product(s) : BPX-601,Rimiducid

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 02, 2020

                          Lead Product(s) : CAR-T Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank